Key Highlights

  • Vir Biotechnology shares were trading down 17.7% at USD 9.98 on Friday, November 13, 2026, in market data, implying a prior close of about USD 12.13 (calculated) against a last reported price of USD 13.13 on November 11.
  • A preliminary prospectus supplement dated November 12, 2026 covers a proposed public offering of common stock; the share count, price and proceeds were blank in the version reviewed, and underwriters hold a 30-day option.
  • The Phase 3 ECLIPSE 1 trial, announced November 9, met its primary endpoint: 44% of treated patients had undetectable virus and normalized liver enzymes at week 48, against 0% of the delayed-treatment group at week 12.
  • Cash and investments were USD 901.3 million on September 30, 2026, the third-quarter net loss was USD 96.3 million, and 169,414,129 shares were outstanding on that date.

Offering Filed Three Days After the Trial Win

Vir Biotechnology (NASDAQ:VIR) was trading down 17.7% at USD 9.98 on Friday, November 13, 2026, in market data, the figure of record for the live session only. The company announced positive Phase 3 data on November 9, and published coverage put the gain that day anywhere from about 11.75% to 22%, a conflict that was not resolved. On November 12 it filed a preliminary prospectus supplement for a public offering of common stock, with the final terms blank. No release giving the final price was found, so a link between the fall and the offering is an inference from timing, not a confirmed cause.

What ECLIPSE 1 Showed in Chronic Hepatitis Delta

Vir develops antibody and small interfering RNA medicines. ECLIPSE 1 enrolled 124 adults with chronic hepatitis delta, randomized 2 to 1 to monthly subcutaneous injections of tobevibart and elebsiran or delayed treatment. At week 48, 79% of treated patients had undetectable hepatitis Delta virus against 0% in the delayed-treatment group, including 85% of those with cirrhosis and 73% without. One grade 3 treatment-related adverse event occurred, with no discontinuations. The company said the combination remains subject to regulatory review, and no filing timeline was found. ECLIPSE 2 and 3 data are expected in the first quarter of 2027.

Cash Runway, Dilution Risk and the Offering Use of Proceeds

The filing says proceeds, with existing cash, will fund pre-commercial activities for the hepatitis delta program, the oncology T-cell engager platform and general corporate purposes. Before the offering, cash and investments of USD 901.3 million, about USD 991 million including proceeds received from Gilead in October, were guided to last into the second half of 2028. The third-quarter net loss of USD 96.3 million compares with USD 163.1 million a year earlier. Dilution cannot be calculated without the final share count and price. Selling after a sharp rally is a common pattern, and the risk is further pressure if pricing was at a discount. The company also reported progress with VIR-5500, which has FDA Fast Track Designation in late-line prostate cancer, with pivotal trials with Astellas targeted for 2027.

Where Things Stand

The most likely driver is the stock offering, but that is an inference from timing. Vir Biotechnology (NASDAQ:VIR) filed for a public offering on November 12, 2026 after Phase 3 data on November 9, and the final terms were not found. The trial data were strong on virus suppression, yet new shares dilute holders, and today's 17.7% fall to USD 9.98 gives back much of the rally. Watch for the final pricing, regulatory plans for hepatitis delta and the first-quarter 2027 ECLIPSE 2 and 3 data.